CDK1 in Breast Cancer: Implications for Theranostic Potential

Author(s):

Sepideh Izadi, Afshin Nikkhoo, Mohammad Hojjat-Farsangi, Afshin Namdar, Gholamreza Azizi, Hamed Mohammadi, Mehdi Yousefi and Farhad Jadidi-Niaragh*   Pages 758 - 767 ( 10 )

Abstract:

Breast cancer has been identified as one of the main cancer-related deaths among women during some last decades. Recent advances in the introduction of novel potent anti-cancer therapeutics in association with early detection methods led to a decrease in the mortality rate of breast cancer. However, the scenario of breast cancer is yet going on and further improvements in the current anti-cancer therapeutic approaches are needed. Several factors are present in the tumor microenvironment which help to cancer progression and suppression of anti-tumor responses. Targeting these cancer-promoting factors in the tumor microenvironment has been suggested as a potent immunotherapeutic approach for cancer therapy. Among the various tumorsupporting factors, Cyclin-Dependent Kinases (CDKs) are proposed as a novel promising target for cancer therapy. These factors in association with cyclins play a key role in cell cycle progression. Dysregulation of CDKs which leads to increased cell proliferation has been identified in various cancers, such as breast cancer. Accordingly, the development and use of CDK-inhibitors have been associated with encouraging results in the treatment of breast cancer. However, it is unknown that the inhibition of which CDK is the most effective strategy for breast cancer therapy. Since the selective blockage of CDK1 alone or in combination with other therapeutics has been associated with potent anti-cancer outcomes, it is suggested that CDK1 may be considered as the best CDK target for breast cancer therapy. In this review, we will discuss the role of CDK1 in breast cancer progression and treatment.

Keywords:

Cyclin-dependent kinase, CDK1, breast cancer, CDK inhibitors, treatment, thernostics.

Affiliation:

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Bioclinicum, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Department of Oncology, Cross Cancer Institute, The University of Alberta, Edmonton, Alberta, Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz

Graphical Abstract:

Read Full-Text article